Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03089281 · ClinicalTrials.gov registry record · NA
Strategic Management to Optimize Response To Cardiac Resynchronization Therapy
A NA study of Heart Failure, sponsored by Boston Scientific Corporation.
- Completed
- Registry status
- NA
- Development phase
- 699
- Enrollment target
- 20
- Study locations
NCT03089281: Completed NA study of Heart Failure, sponsored by Boston Scientific Corporation.
NCT03089281 is a NA study of Heart Failure that has completed, run by Boston Scientific Corporation. The registered enrollment target is 699 participants, below the 2,047-participant average among 397 other Heart Failure trials with a reported enrollment target (66% lower). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03089281, a NA study of Heart Failure, has completed, sponsored by Boston Scientific Corporation.
- COMPLETED
- Registry status
- NA
- Development phase
- 699 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objective is to evaluate the benefit of the SmartDelay™ algorithm in patients with a prolonged RV-LV interval.
Primary Outcome
Comparing cardiac resynchronization therapy (CRT) response rates between AV Delay programming schemes defined by SmartDelay or a Fixed AV Delay of 120ms. A negative change in LVESV is considered an improvement; CRT response is defined by a change in Left Ventricular End Systolic Volume (LVESV) \< -15% at 6 months compared to pre-implant baseline.
Conditions Studied
Interventions
- DEVICE CRT-D
Study Locations (20)
Florida
- Baptist Health Research Institute - Jacksonville
- Watson Clinic Center for Research, Inc - Lakeland
- Winter Haven Hospital - Winter Haven
Alabama
- Affinity Hospital, LLC d/b/a Granview Medical Center - Birmingham
- Heart Center Research LLC - Huntsville
California
- Glendale Adventist Medical Center - Glendale
- Salinas Valley Memorial Healthcare System - Salinas
Georgia
- Emory University Hospital - Atlanta
- Northside Hospital - Atlanta
Illinois
- The University of Chicago - Chicago
- St. John's Hospital - Springfield
Kentucky
- St. Elizabeth Healthcare - Edgewood
- Baptist Health Lexington - Lexington
Massachusetts
- Lahey Hospital and Medical Center - Burlington
- Southcoast Health - Fall River
Arizona
- University of Arizona Sarver Heart Center - Tucson
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 699 participants |
| Start Date | 2017-08-01 |
| Est. Completion | 2020-09-15 |
| Phase | NA |
What the finished NCT03089281 record still lists
NCT03089281 is an interventional study that assigns participants to a tested intervention. The registered 699 participants enrollment target is mid-sized for trials with a published cap, below the 2,047-participant average among 397 other Heart Failure trials with a reported enrollment target (66% lower).
The record links to 1 condition, with Heart Failure appearing as the primary indexed condition, and to 1 intervention - of which CRT-D is the first listed.
NCT03089281 names 20 study sites across 12 states, led by Florida, Alabama, California.
Frequently Asked Questions
What is clinical trial NCT03089281 about?
NCT03089281 is a clinical study titled "Strategic Management to Optimize Response To Cardiac Resynchronization Therapy". The primary objective is to evaluate the benefit of the SmartDelay™ algorithm in patients with a prolonged RV-LV interval.
What is the current status of trial NCT03089281?
This trial is currently completed. It is a NA study. The enrollment target is 699 participants. The study started on 2017-08-01. Estimated completion is 2020-09-15.
What conditions does trial NCT03089281 study?
This clinical trial studies the following conditions: Heart Failure.
What interventions are being tested in trial NCT03089281?
The interventions under investigation include: CRT-D (DEVICE).
Who is sponsoring clinical trial NCT03089281?
This trial is sponsored by Boston Scientific Corporation, which has 280 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03089281 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Delaware. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heart Failure
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03089281's enrollment target sits among peer trials
699 85th of 397 higher than 313 of 397 other Heart Failure trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Heart Failure trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Early Feasibility Study of the NORM™ System in Heart Failure Patients (FUTURE-HFII)
RECRUITING · NA
-
Diuretics Alone vs. Aortix Endovascular Device for Acute Heart Failure
RECRUITING · NA
-
iCardia4HF: Multi-component mHealth Intervention for Patients With Heart Failure
RECRUITING · NA
-
Optimizing Heart Failure Therapies Among Patients With Limited Access in Denver
RECRUITING · NA
-
Hemodynamic Monitoring to Prevent Adverse Events foLlowing cardiOgenic Shock Trial
RECRUITING · NA
-
Effect of a Quality Improvement Initiative to Address Social Determinants of Health on Rehospitalization Rates in Patients With Heart Failure
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07187115 · 699 participants · NA
A Global Study Comparing Pulsed Field Ablation With Electrographic Flow Mapping Versus Posterior Wall Ablation for Persistent Atrial Fibrillation
- NCT00900419 · 700 participants
Biomarkers in Patients With Respiratory Tract Dysplasia or Lung Cancer, Head and Neck Cancer, or Aerodigestive Tract Cancer and in Normal Volunteers
- NCT01804686 · 700 participants · Phase 3
A Long-term Extension Study of PCI-32765 (Ibrutinib)
- NCT02107989 · 700 participants
Noninvasive Pre-surgical Evaluation of Patients With Focal Epilepsy and Establishment of a Normative Imaging Database
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI